AEPCX
Price
$59.60
Change
+$0.39 (+0.66%)
Updated
Jul 31 closing price
Net Assets
140.66B
CIESX
Price
$29.76
Change
-$0.27 (-0.90%)
Updated
Jul 31 closing price
Net Assets
835.36M
Interact to see
Advertisement

AEPCX vs CIESX

AEPCX vs CIESX Comparison Chart in %
View a ticker or compare two or three
VS
AEPCX vs. CIESX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AEPCX is a Buy and CIESX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
AEPCX has more cash in the bank: 141B vs. CIESX (835M). AEPCX pays higher dividends than CIESX: AEPCX (2.13) vs CIESX (1.14). AEPCX was incepted earlier than CIESX: AEPCX (25 years) vs CIESX (7 years). AEPCX (1.58) is less costly to investors than CIESX (0.88). AEPCX is a more actively managed with annual turnover of: 50.00 vs. CIESX (29.00). AEPCX has a lower initial minimum investment than CIESX: AEPCX (250) vs CIESX (5000000). CIESX annual gain was more profitable for investors over the last year : 16.37 vs. AEPCX (6.78). CIESX return over 5 years is better than : 15.52 vs. AEPCX (-7.30).
AEPCXCIESXAEPCX / CIESX
Total Expense Ratio1.580.85186%
Annual Report Gross Expense Ratio1.580.88180%
Fund Existence25 years7 years-
Gain YTD3.16810.50930%
Front LoadN/AN/A-
Min. Initial Investment25050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets141B835M16,886%
Annual Yield % from dividends2.131.14187%
Returns for 1 year6.7816.3741%
Returns for 3 years14.7030.6248%
Returns for 5 years-7.3015.52-47%
Returns for 10 years38.82N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SLGYX23.050.19
+0.83%
Saratoga Large Capitalization Growth A
JHAAX10.710.01
+0.09%
JHancock Multi-Asset Absolute Return A
PCGRX28.71-0.07
-0.24%
Victory Pioneer Mid Cap Value A
ECASX25.03-0.16
-0.64%
Eaton Vance Atlanta Capital SMID-Cap C
FBTIX49.83-1.21
-2.37%
Fidelity Advisor Biotechnology I